153 results about "Glutathione-SH" patented technology

A composition for treatment of inflammatory skin conditions is provided having a carrier; reduced glutathione; and alpha lipoic acid. The composition preferably contains 25% to 60% by weight glutathione; and 0.5% to 5% by weight alpha lipoic acid. The composition is useful for topical treatment of psoriasis and other inflammatory skin diseases.

The present invention provides, inter alia, compounds having the structure (1) compositions containing such compounds are also provided. Methods for using such compounds or compositions for treating or ameliorating the effects of a cancer having a cell that harbors an oncogenic RAS mutation, for modulating a lipoxygenase in a ferroptosis cell death pathway, and for depleting reduced glutathione (GSH) in a cell harboring an oncogenic RAS mutation are further provided.

The invention proposes the sure of reduced glutathione in a liposome (liposomal reduced glutathione) for the oral administration of a therapeutically effective amount to ameliorate the progression of vascular disease, including atherosclerosis, diabetes, hypertension, narrowing of arteries leading to decreased blood flow, ischemic events, and the formation of blood clots, abnormal platelet aggregation, and thrombotic events, by reducing the amount and effect of oxidized cholesterol, oxidized HDL and oxidized LDL. The invention also proposes combining liposomal encapsulated glutathione with statin drugs to improve the effect of lowering not only cholesterol but also the oxidized cholesterol as well as oxidized HDL and oxidized LDL. The invention also proposes combining liposomal encapsulated glutathione with CoQ10 as a therapy for vascular disease and management of side effects of statin therapy.

The present invention relates to novel methods of using blood substitutes to treat acute blood loss and novel pharmaceutical compositions comprising blood substitutes. Blood substitutes useful for the methods of the present invention can (1) induce expression of erythropoietin as tested in a cell culture under normoxic conditions, and / or (2) induce erythropoiesis under normoxic conditions as measured by (a) a decrease in the doubling time of the subject's hematocrit or hemoglobin, and / or (b) an increase in the subject's circulating erythropoietin level. Blood substitutes useful for the pharmaceutical compositions of the present invention can (1) stabilize HIF-1 alpha expression, and / or (2) down regulate NF-kappa B. Preferably, the blood substitutes are cross-linked hemoglobin blood substitutes, or more preferably, cross-linked hemoglobins that comprise a hemoglobin that is cross-linked intramolecularly with periodate-oxidized ATP, cross-linked intermolecularly with periodate-oxidized adenosine, and conugated with reduced glutathione.

The invention provides a composition for preventing or treating infectious diseases of a virus belonging to the Coronavirus family or Flavivirus family, the composition containing one or more substances selected from reduced glutathione or oxidized glutathione or pharmaceutically acceptable salts thereof and catechin, and a composition for preventing or treating infectious diseases of a virus belonging to the Coronavirus family or Flavivirus family, the composition containing reduced glutathione or oxidized glutathione or pharmaceutically acceptable salts thereof and catechin.

The invention relates to a method for synthesizing reduced glutathione. The method comprises the following steps of: (1), preparing R-glutamic acid; (2), preparing R-glutamic anhydride; (3), preparing R-glutamic-alpha-benzyl ester; (4), preparing R-glutamic-alpha-benzyl ester-gamma-acyl chloride; (5), preparing R-glutamic-alpha-benzyl ester-cystine; (6) preparing glycine-benzyl ester hydrochloride; (7) preparing bisR-S-S-glutathione-tetrabenzyl ester; and (8), preparing the reduced glutathione. The method has a simple and environmentally-friendly process step; the synthesizing steps are shortened; the yield is improved; and the used raw materials have relatively low cost. The method is the method for synthesizing the reduced glutathione, which has relatively high innovativeness.

The invention belongs to the field of nano-biomedicine, and relates to a Cu-amino acid composite up-conversion nano material capable of realizing chemical kinetic therapy and near-infrared light-activated up-conversion fluorescence imaging simultaneously and a preparation method of the Cu-amino acid composite up-conversion nano material. The Cu-amino acid composite up-conversion nano material cansimultaneously realize the chemical kinetic therapy and the near-infrared light-activated up-conversion fluorescence imaging, and has a uniform sphere shape and a clear core-shell structure; the innercore is rare earth fluoride nanoparticles, and the outer shell is a Cu-L-cysteine complex; the Cu-amino acid composite up-conversion nano material can be enriched in tumor sites through an EPR effect, and is specifically activated by the tumor microenvironment without causing damage to normal tissues; the Cu-amino acid composite up-conversion nano material can consume reduced glutathione over-expressed in cells and release cuprous ions with Fenton-like reactivity, and at the same time, an efficient Fenton reaction is performed to produce .OH having strong cytotoxicity; and under the irradiation of near-infrared light, the Cu-amino acid composite up-conversion nano material can emit ultraviolet and visible light, and realize the imaging function that an ordinary chemical kinetic reagent does not have.

The invention discloses an application of a cleaning fluid after chemical mechanical polishing. The invention specifically discloses the application of the cleaning fluid to cleaning of a semiconductor device after chemical mechanical polishing. The raw materials of the cleaning fluid comprise the following components by mass: 0.01%-25% of strong base, 0.01%-30% of alcohol amine, 0.001%-1% of antioxidants, 0.01%-0.1% of polypeptide, 0.01%-0.1% of amino acid, 0.01%-10% of corrosion inhibitors, 0.01%-10% of chelating agents, 0.01%-5% of surfactants and 28.9%-89.9% of water, and the sum of the mass fractions of all the components is 100%, wherein the amino acid is a combination of histidine and cysteine, and the polypeptide is a combination of reduced glutathione (peptide A) and oxidized glutathione (peptide B). The cleaning fluid is higher in cleaning capacity, lower in corrosion rate, higher in BTA removal capacity and higher in stability, and the effects of cleaning, corrosion inhibition and BTA removal can be achieved at the same time.

The use of glutathione to treat or prophylax viral, bacterial, chemical, and nuclear agents, or to treat or prophylax radiation injury to humans due to release of radioactive elements. The preferred formulation is an oral dosage form, with reduced glutathione stabilized by ascorbic acid, packaged to under controlled humidity and temperature conditions to ensure creation of charge transfer complexes that ensure consistent packaging, insignificant oxidation during packaging and subsequent normal storage, and high oral bioavailability for humans.